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Veterans returning from the Gulf War of
1990–1991 described multiple-organ symp-
toms that included chemical sensitivity,
chronic fatigue, ﬁbromyalgia, neurocognitive
deﬁcits, irritable bowel syndrome, headaches,
joint pains, fever, and a general unwellness,
referred to as Gulf War syndrome (GWS)
(Cherry et al. 2001; Gray et al. 2002; Haley
and Kurt 1997; Hallman et al. 2003; Iowa
Persian Gulf Study Group 1997; Kang et al.
2002; Kroenke et al. 1998; Lashof and
Cassells 1998). GWS probably has a multiple-
factorial etiology involving possible chemical
exposures (Haley and Kurt 1997). The sus-
pected factors include Arabian sand dust,
low-level chemical and biological warfare
agents, pyridostigmine bromide, N,N-diethyl-
m-toluamide, organophosphate pesticides,
depleted uranium, combustion by-products of
oil well ﬁres, diesel exhaust, petroleum prod-
ucts, and infectious agents (Abou-Donia et al.
2001; Kurt 1998; Moss 2001; Schumm et al.
2002; Sharabi et al. 1991). Explanations for
GWS include genetic polymorphism of para-
oxonase (PON1) (Haley et al. 1999; La Du
et al. 2001), butyrylcholinesterase (Shen 1998),
glutathione S-transferase and cytochrome
P4501A1 (Whatt et al. 2000), and, more
recently, neuropathy target esterase (Winrow
et al. 2003). Clinical ﬁndings include abnor-
malities of basal ganglia and brainstem (Haley
et al. 2000) and recently reported increased
neurologic diseases and, particularly, an
increased rate of amyotrophic lateral sclerosis
(ALS) (Haley 2003; Horner et al. 2003).
Moreover, Gulf War Veterans have an increase
in serum RNAs with segments homologous to
chromosome 22q11.2 ALU, indicating a
rearrangement of this antigen-responsive spot
(Urnovitz et al. 1999). 
The symptoms of GWS are remarkably
similar to those of chronically ill individuals
with immunologic alterations after exposure
to chlorinated pesticides (McConnachie and
Zahalsky 1991, 1992), chlorpyrifos (Thrasher
et al. 1993, 2001), formaldehyde (Thrasher
et al. 1987, 1990), silicone breast implants
(Vojdani et al. 1993), and solvents (Vojdani
et al. 1992). Reported immunologic abnor-
malities suggest a shifting of the immune sys-
tem to TH1 and/or TH2 profiles (Ferguson
and Cassaday 2001/2002; Patarca 2001;
Rook and Zumia 1997; Zhang et al. 1999).
Moreover, levels of complement components
(C3a, C4a, C5a) are signiﬁcantly increased in
chronic fatigue syndrome (CFS) patients ver-
sus controls (Sorensen et al. 2003). As a
result, we were asked to examine sympto-
matic GWS patients to determine if they had
immunologic alterations similar to those seen
in CFS (Levine et al. 1998; Patarca 2001;
Rosenbaum et al. 2002), chemically exposed
individuals (Baj et al. 1994; Cooper et al.
2002; Griem et al. 1998; Thrasher et al.
1993; Vojdani et al. 1992), and earlier reports
of GWS (Rook and Zumia 1997).
Materials and Methods
Subjects. Immunosciences Lab., Inc. was
approached by R. Haines of the U.S. Army
requesting immune testing of 10th Army Unit
Gulf War Veterans who had GWS with com-
mon symptoms (joint pain, fatigue, headache,
memory or concentration difﬁculties, sleep dis-
turbances, and rash). Haines, with the help of
medical doctors, initially selected 50 sympto-
matic patients (group A), followed at a later
date by an additional 50 symptomatic patients
(group B). Medical records and health histories
were not forwarded for us to review. Controls
consisted of two groups: group C consisted of
50 asymptomatic vaccinated veterans of the
10th Army Unit who were not deployed to the
Persian Gulf, and group D consisted of
50 healthy asymptomatic subjects sent to the
laboratory by treating physicians for annual
checkups. Patients ranged from 34 to 56 years
of age and consisted of 74 males and
26 females. The controls were age and sex
matched. Venous blood was received within
24 hr from different clinics from several states
and immediately processed for immunologic
testing. Groups A and C underwent immuno-
logic testing in 1993. The testing of groups B
and D occurred over an extended period from
1995 through 1999. The tests were done at no
charge to the U.S. Army and as a result were
limited to immune parameters presented
below. The test requests were properly docu-
mented and kept in a conﬁdential ﬁle. All sub-
jects gave their informed consent and allowed
inclusion of their data in this report without
disclosure of their identity in the publication.
Basic laboratory tests. Patients and con-
trols underwent complete blood counts
(CBC); chemistry, including lipids, liver
enzymes, thyroid function [triiodothyronine
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mone (TSH)]; and basic immunology [anti-
nuclear antibody (ANA), rheumatoid factor
(RF), and total IgA, IgG, and IgM].
Lymphocyte subset enumeration. Direct
immunofluoresence staining of cell surface
antigen was accomplished using the Becton-
Dickinson FACScan Immunocytometry
system (San Jose, CA). The peripheral mono-
nuclear cells are treated with monoclonal anti-
bodies conjugated to ﬂuorescein isothiocyanate
(FITC) or phycoerythrin (PE). The blood
samples were ﬁrst treated with red blood cell
lysing solution. Cells were then washed,
stained with monoclonal antibody, and then
analyzed with the FACScan flow cytometer.
We used the following pairs of FITC- or
PE-conjugated monoclonal antibodies: CD45/
CD14 for quality control check, CD3/CD4
for T-helper cells, CD3/CD8 for suppressor
cells, CD3/CD19 for T and B cells, and
CD3/CD16 plus CD56 for natural killer
(NK) cells (NKHT3+ and NKHT3–). Using
these sets of monoclonal antibodies, we deter-
mined the percentage of positively stained cells
for each marker pair and the percentage of
double stained cells. 
Preparation of peripheral blood leukocytes.
Leukocytes were prepared from heparinized
peripheral venous blood by Ficol-Hypaque
density gradient (Sigma Chemical Company,
St. Louis, MO). Cells were washed three times
with Hanks balanced salt solution and resus-
pended to a concentration of 107 cells/mL in a
complete medium (CM) that consisted of
RPMI-1640 supplemented with 10% fetal calf
serum and 1% antibiotics (100 U penicillin
and 100 µg/mL streptomycin). We examined
purity of the cells by flow cytometry using
CD45/CD14 monoclonal antibodies; purity
was > 95%. Cells were used for different func-
tional assays within 1 hr of isolation.
NK cell cytotoxicity assay. We used a stan-
dard 4-hr 51Cr-release assay (Whiteside et al.
1990) to determine NK cell cytotoxicity.
Brieﬂy, we added 1 × 1045 1 Cr-labeled K562
tumor target cells in 0.1 mL CM to different
wells of a microtiter plate. Effector cells were
then pipetted into triplicate wells for each dilu-
tion to give effector:target ratios of 6:1, 12:1,
24:1, and 48:1. After a 4-hr incubation at
37°C, the plates were centrifuged at 1,400 rpm
for 4 min, and 0.1 mL of supernatant was col-
lected from each well and placed in a gamma
counter. The percentages of isotope released
were calculated using the following formula: 
[1]
The results of NK cell assay for each
effector:target ratio was expressed in terms of
lytic units (LU), calculated as described by
Whiteside et al. (1990). 
Lymphocyte mitogenic assay. Lymphocytes
were isolated and tested for mitogenic activity
as described by Fletcher et al. (1992) and
Maino et al. (1995). Brieﬂy, 5 × 105 lympho-
cytes per 0.1 mL CM were cultured in flat-
bottom microtiter plate wells. Cells from
patients and controls, as well as cells with
known mitogenic stimulation, were cultured
with or without an optimal concentration of
either phytohemagglutin (PHA; 25 µg/mL;
Grand Island Biological Company, Grand
Island, NY) or pokeweed mitogen (PWM; 5
µg/mL; Sigma Chemical Company). After
48 hr of incubation, the cells were harvested
and stained with CD69 monoclonal antibody
conjugated to ﬂuorescent dye and analyzed by
flow cytometry. Wells with no mitogens
added (negative control) provided information
about the media and cells used in the assay so
we could determine possible nonspeciﬁc mod-
ulatory activity. Values for patients and con-
trols were compared with the daily negative
and positive control for each assay. Results
were calculated using the following formula: 
[2]
We estimated three stimulation levels: low,
< 75% of the number of control cells; normal,
75–125% of the number of control cells; and
elevated, > 125% of the number of control
cells. 
Myelin basic protein antibody. The anti-
body to human myelin basic protein (MBP)
was analyzed as previously described (Vojdani
et al. 1992). Briefly, MBP (Sigma Chemical
Co.) was checked for purity by polyacrylamide
gel electrophoresis (Diebler et al. 1972).
Antisera to MBP were induced in rabbits by
repeated injection of the protein in complete
Freund’s adjuvant. Antibody activity in the
rabbit sera and the patient and control samples
was detected by adding different dilutions
(1:100–1:10,000) of sera to wells of a
microtiter plate previously coated with MBP.
MBP (250 µg/mL) was dissolved in carbonate
buffer (pH 9.6), and 200 µL of this solution
was added to each well. After incubation,
washing, and blocking with 1.5% bovine
serum albumin plus gelatin, 200 µL of either
diluted rabbit or human serum was added to
the wells. Incubation was repeated for 1 hr at
25°C, and the sera were shaken out of the
wells, which were then washed ﬁve times with
wash solution. Next, 200 µL peroxidase-
conjugated goat anti-rabbit or goat anti-
human IgM (optimal dilution) was added to
the appropriate well. After incubation and
repeated washing, 200 µL substrate was added
to each well. Plates were incubated for 1 hr at
room temperature and read in a microtiter
reader at 480 nm wavelength. We plotted a
titration curve using rabbit antisera, and com-
pared patient and control sera with this stan-
dard curve. Results are expressed by the ELISA
(enzyme-linked immunosorbent assay) values.
Striated and smooth muscle antibody assay.
We purchased skeletal muscle myoblast cell
line CRL-1769 and smooth muscle cell line
ATCC CRL-1444 from American Type
Culture Collection (Rockville, MD). Cells
were grown in Dulbecco’s modified Eagle’s
medium (90%) and fetal bovine serum (10%).
After 7 days in culture, the cells were harvested,
sonicated, and used for coating ELISA plates.
Each ELISA microplate well was coated with
100 µL cell lysate containing 10 µg protein in
0.1 M carbonate buffer (pH 9.5). Plates were
incubated overnight at 4°C and then washed
three times with 200 µL Tris-buffered saline
containing 0.05% Tween 20 (pH 7.4). With
the exception of goat anti-human IgG F(ab´)2,
all other steps were similar to the MBP ELISA
method described above. To detect nonspeciﬁc
binding, we used all reagents except human
serum in several control wells and coated some
wells with different tissue antigens.
Immune complexes. We measured IgG,
IgM, and IgA immune complexes by coating
microtiter plates with anti-C1q. Addition of
serum, second antibody, and substrate was
similar to procedures for measuring MBP
antibody by ELISA.
Antibodies to viruses. Antibody titers
against Epstein-Barr virus (EBV); cytomegalo-
virus (CMV); herpes simplex virus type 1
(HSV-1), HSV-2, HHV-6; and Varicella zoster
virus (VZV) were measured by ELISA using
kits from Diamedix (Miami, FL).
Determination of expected ranges. We
obtained expected ranges as follows: 
• Earlier publications.
• Suppliers of the CD markers (Becton-
Dickinson) carried out in-house veriﬁcation
using blood from 100 healthy controls from
which the means, SDs, and 95% conﬁdence
intervals (CIs) were determined (Babcock
et al. 1987, Shearer et al. 2003). 
• The manufacturers of the immune complex
and viral antibody test kits provided an
expected range with their products (Abbas et
al. 1994, Christenson et al. 1992, Matheson
et al. 1990, Shehab and Brunell 1983).
•W e obtained expected ranges for NK cell
activity from Whiteside et al. (1990) and
confirmed them in our laboratory by per-
forming the assay on 500 specimens from
healthy subjects. 
• We determined expected ranges for PHA and
PWM mitogenesis and for autoantibodies to
MBP and striated and smooth muscle in-
house using 100 healthy controls for which
means, SDs, and 95% CIs were calculated.
Percentage of stimulation
Activated sample Unstimulated sample
Activated control Unstimulated control
   =
×
–
–
100
   
Percentage of lysis
Experimental release Spon eous release
Total release Spon eous release
   =
×
– tan
– tan
100
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of suppliers’ recommendations and in-house
quality control.
Statistics. We used two-sided critical t-tests
for comparison of independent means and
Z-tests for comparison of independent propor-
tions as described by Bourke et al. (1985).
Results
Basic laboratory tests. We observed some vari-
ations from expected normal ranges in both
controls and patients, respectively, as follows:
CBC, 21 and 27%; blood glucose, 12 and
9%; lipid proﬁle, 18 and 22%; liver enzymes,
14 and 19%; T3, T4, and TSH, 9 and 12%;
ANA, 7 and 11%; RF, 10 and 14%; and
immunoglobulins, 6 and 8%. Z-tests for
independent proportions revealed no signiﬁ-
cant difference between controls and patients
for each test.
Comparison of patients (groups A and B)
and controls (groups C and D). We analyzed
the data to determine if differences existed
between patient groups A and B and their
controls for each tested immune parameter
(data not shown). No significant differences
were found; therefore, we combined patient
groups A and B and control groups C and D
for further statistical analysis. In addition, we
observed no differences between males and
females in any of the groups. 
CD3 T cells. The percentages of CD3
T cells present in the peripheral blood of con-
trols versus patients are presented in Table 1.
The mean percentage of CD3 cells in patients
(72.8 ± 10.3%, mean ± SD) was slightly
higher compared with the controls (71.6 ±
7.3%), but the difference was not signiﬁcant.
However, the percentage of individuals that
fell outside of the expected range of 53–79%
CD3 cells was different between the two
groups; 2% of controls and 9% of patients
had < 53% CD3 cells, and 5% of controls
and 30% of patients had > 79%. The critical
Z- and p-values for variance from normal dis-
tribution were signiﬁcant (p < 0.05).
CD19 B cells. The percentages of CD19
B cells present in the peripheral blood of con-
trols versus the patients are presented in
Table 1. The mean percentage of B cells in the
patients (16.1 ± 6.0%, mean ± SD) was greater
than that for the controls (11.5 ± 3.1%). The
difference between the two means was highly
signiﬁcant (t = 11.402, p < 0.001). The distrib-
ution of B cells outside of the expected range
(5–15%) was also different when the patients
were compared with the controls. Forty-nine
percent of patients and 5% of controls had
> 15% B cells, whereas 0% of controls and 4%
of patients had < 5% B cells. The critical
Z-values for variance from normal distribution
were signiﬁcant (p < 0.01).
CD4:CD8 ratio. The CD4:CD8
(helper:suppressor) ratios for controls and
patients are listed in Table 1. The ratio was
significantly (p < 0.001) elevated in patients
(2.23 ± 0.87, mean ± SD) compared with
controls (1.74 ± 0.34). The Z-values for the
percentage of patients with values outside the
expected distribution of the CD4:CD8 ratio
were significantly different compared with
those of the controls (p < 0.001). 
NK cell activity. The data obtained for
NK lytic activity are presented in Table 2. The
lytic activity was signiﬁcantly less (p < 0.001)
in patients (24.8 ± 16.5) than in controls
(37.3 ± 26.4). The percentages of individuals
with > 50 LU were not different between the
two groups (p = not signiﬁcant), whereas the
p-value for the percentage of patients with
<2 0LU was signiﬁcant (p < 0.01).
Mitogen stimulation. The results of PHA
and PWM stimulation of peripheral lympho-
cytes in the controls and patients are summa-
rized in Table 2. The mean percentage of
stimulation by either PHA or PWM was not
different between controls and patients.
However, the distribution of stimulation values
did differ between the two groups. For PHA,
more GWS patients (32%) had a stimulation
index < 75% of expected (p < 0.01) but 4% of
patients had a stimulation index > 125%
(p < 0.05). For PWM stimulation, an increased
percentage of patients had an index < 75%
(p < 0.01), whereas the difference between the
percentages of patients (4%) and controls (1%)
with values > 125% were not signiﬁcant.
Autoantibodies. The observations for IgM
anti-MBP in the controls and patients are
shown in Table 3. The mean ELISA units for
IgM antibodies were signiﬁcantly (p < 0.001)
greater in patients (45.9 ± 35.8) than in con-
trols (28.4 ± 13). The Z-value for the percent-
age of patients with > 50 ELISA units was
significant (p < 0.001). The mean value for
the patients with IgM titers > 50 ELISA units
was 75.7 ± 15.9.
Antibodies to muscle (striated and smooth).
The results for IgG antibodies to both smooth
and striated muscle are shown in Table 3. The
mean IgG titers observed in the patients (42.8
± 72.3) were signiﬁcantly (p < 0.001) greater
than those for the controls (15.9 ± 11.4).
Immune complexes. The observations on
immune complexes found in the peripheral
blood of controls and patients are summarized
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Table 1. Percentage of CD3 T cells and CD19 B cells and CD4:CD8 ratios in controls and patients.
Percent Expected Percent of subjects outside the expected range
Cell type or ratio (mean ± SD) range (%) Below bottom of range Above top of range
CD3 T cells
Controls 71.6 ± 7.3 53–79 2 5
Patients 72.8 ± 10.3 53–79 9 30
Z = 2.17 Z = 4.65
p < 0.05 p < 0.01
CD19 B cells
Controls 11.5 ± 3.1 5–15 0 5
Patients 16.1 ± 6.0 5–15 4 49
Z = 6.38 Z = 11.4
p < 0.01 p < 0.001
CD4:CD8 ratio
Controls 1.74 ± 0.34 1.0–2.5 0 3
Patients 2.23 ± 0.87 1.0–2.5 4 33
Z = 2.2 Z = 5.33
p < 0.05 p < 0.001
Controls and patients were compared using Student’s t-test. Critical Z-values were obtained for the normal distribution.
Table 2. NK cell activity and lymphocyte stimulation with PHA and PWM in controls and patients.
Lytic units (LU)
Percent Expected Percent of subjects outside the expected range
Cell type (mean ± SD) range (%) Below bottom of range Above top of range
NK cell activity
Controls 37.3 ± 26.4 20–50 8 9
Patients 24.8 ± 16.5 20–50 47 6
Z = 6.35 Z = 0.80
p < 0.01 NS
PHA
Controls 84.9 ± 20.2 75–125 6 0
Patients 84.4 ± 19.9 75–125 32 4
Z = 4.6 Z = 2.02
p < 0.01 p < 0.05
PWM
Controls 85.4 ± 11.5 75–125 7 1
Patients 87.3 ± 18.6 75–125 23 4
Z = 3.16 Z = 1.35
p < 0.01 p < 0.05
NS, not signiﬁcant. Controls and patients were compared using Student’s t-test and Z-test. in Figure 1. Immune complexes were signiﬁ-
cantly (p < 0.001) elevated in the patients
(52.1 ± 18.5 mEq/mL) compared with con-
trols (34.5 ± 14.3 mEq/mL) (Figure 1A). In
addition, the percentage of patients with
immune complexes > 50 mEq/mL was signiﬁ-
cantly higher than that for controls (p < 0.01)
(Figure 1B).
Antibodies to viruses. The results obtained
on antibodies to viruses are presented in
Table 4. Mean titer levels for each virus were
signiﬁcantly (p < 0.001) higher in the patients
than in controls.
The differences in the mean titer levels
between the patients and controls resulted
from a disproportionate number (percentage)
of patients who had elevated titers to each
virus. For example, the mean IgM antibodies
to EBV viral capsid antigen (VCA) was 724
± 401 ELISA units for the 56 individuals that
fell above the maximum expected titer of
300 ELISA units. Similar observations were
evident for each of the remaining viruses.
Z-values for the percentage of patients with
elevated titers were significantly different
from those for controls (Figure 2).
Discussion
The patients and the controls that underwent
immunologic testing were from two different
time periods, 1993 versus 1995–1999. In addi-
tion, the two sets of controls were different:
one consisted of asymptomatic U.S. Army sol-
diers who did not serve in the Gulf War, and
the other consisted of healthy individuals
undergoing annual checkups. Therefore, we
deemed it necessary to determine if there were
any differences between the groups. t-Tests
comparing the means of each immune parame-
ter revealed that no differences existed between
the two sets of patients as well as the two sets
of controls (data not shown), permitting the
pooling into patients (n = 100) versus controls
(n = 100). This analysis revealed two interest-
ing observations: a) GWS patients had
immunologic alterations approximately 2–8
years after participation in the Gulf War; and
b) the asymptomatic soldiers’ immunologic
findings were no different from those of
healthy individuals undergoing an annual
checkup.
When we analyzed the data on basic labo-
ratory testing (CBC, chemistry, T3, T4, TSH,
RF, and other measures, the differences
between patients and controls were not signif-
icant. Therefore, we conclude that such tests
are of little value in diagnosing GWS.
One of the fundamental issues facing the
ﬁeld of immunotoxicology is the degree of per-
turbation to a given parameter after exposure
to a xenobiotic that translates into a signiﬁcant
health risk. A number of methods have evolved
to address the question of how a chemical or
drug affects the ability of the immune system
to resist challenge by pathogens or abnormal
host cells (e.g., tumor). These include both
functional (i.e., activity of one or more speciﬁc
cell types) as well as host resistance assays. They
were designed to evaluate the overall changes
in the functional integrity of the immune sys-
tem associated with certain chemicals, pharma-
ceuticals, and biotherapeutic molecules
(Cornacoff et al. 1995; Loveless et al. 1997;
Luster et al. 1988, 1993; Smialowicz et al.
1995). Therefore, analysis of circulating lym-
phocyte subpopulations reveals that alterations
do exist in increased T-cell numbers, B-cell
numbers, and CD4:CD8 ratio in these
patients (Table 1). An increased CD4:CD8
ratio indicates an increase in inducer helper
CD4 relative to CD8 suppressor/cytotoxic
cells. These observations are compatible with
previous reports on GWS (Zhang et al. 1999)
as well as those regarding lymphocyte subset
alterations after exposure to xenobiotics (Baj
et al. 1994; McConnachie and Zahalsky 1991,
1992; Thrasher and Broughton 2001; Vojdani
et al. 1992, 1993).
Further assessment of the immune system
of GWS patients was done by measurement of
T- and B-cell function and NK cell activity.
Although the mean values for mitogenic
response to PHA and PWM were not different
in patients versus controls, the percentage of
individuals with abnormally low mitogenesis
was significantly different between the two
groups (Table 2). Such an analysis is appropri-
ate because immune dysregulation can result in
either increased or decreased mitogenic
response in some individuals. Mitogen stimula-
tion is used clinically to assess cellular immunity
in patients with immunodeﬁciency, cancer, and
autoimmunity, as well as to assess the immuno-
toxic potential of drugs and chemicals in
humans and experimental animals (Smialowicz
1995). Similarly, assessment of NK lytic activity
also gives valuable information. The lytic activ-
ity of NK cells (Table 2) was signiﬁcantly lower
in the GWS patients (24.8 ± 16.5) versus the
controls (37.3 ± 26.4). This was also reﬂected
by an elevated number of GWS patients (47%)
with low lytic activity of NK cells. Decreased
numbers of NK cells have been reported in
GWS individuals with chronic fatigue (Zhang
et al. 1999). Furthermore, decreased mitogene-
sis and decreased NK activity have been
reported after exposure to xenobiotics and in
chronic fatigue (Heuser and Vojdani 1997;
Levine et al. 1998; Racciatti et al. 2001;
Vojdani et al. 1992, 1993; Whiteside and
Friberg 1998). Thus, the observed changes in
the functional status of T-, B-, and NK cells in
GWS patients are consistent with immune
alterations in humans after exposure to xeno-
biotics as described above.
The most critical but open question in
immunosurveillance is whether information
on differences between individuals with
abnormal NK, T-, and B-cell function can
predict future development of cancer or auto-
immune diseases. Indications of the signiﬁcant
role for NK cells in preventing the develop-
ment of cancer in both mice and humans have
been reported (Imai et al. 2000; Wilson et al.
2001). A prospective cohort study among a
Japanese general population showed that
medium and high cytotoxic activities were
associated with reduced cancer risk, whereas
low activity was associated with an increased
risk (Imai et al. 2000). Wilson et al. (2001)
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Figure 1. Total level of immune complexes (A) and
percentage of elevation (B) in controls and patients
with GWS. Error bars indicate SD. Controls and
patients were compared using Student’s t-test.
Critical Z-values were also obtained for normal dis-
tribution; p < 0.01, Z = 5.58, t-test = 7.46. 
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Table 3. IgM antibody against MBP and IgG antibodies against smooth and striated muscle in controls and
patients. 
Level of IgM antibody
Expected range Percent of subjects 
Antibody type Mean ± SD (ELISA units) above top of range
Anti-MBP
Controls 28.4 ± 13 0–50 4
Patients 45.9 ± 35.8 0–50 34
Z = 5.57
p < 0.001
Against smooth and striated muscle
Controls 15.9 ± 11.4 0–20 9
Patients 42.8 ± 72.3 0–20 37
Z = 4.70
p < 0.001
Controls and patients were compared using Student’s t-test and Z-test. demonstrated suppressed NK cell activity with
altered host resistance in mice. NK cell activity
was incrementally decreased by intravenous
administration of antibody to NK surface
receptors. After a ≥ 80% decrease in sponta-
neous NK activity, a challenge with ≥ 1 × 103
B16F10 melanoma cells resulted in increased
tumor burden in the lungs (Wilson et al.
2001). Furthermore, when challenged with
1 × 105 melanoma cells, tumor burden was
not increased until spontaneous NK activity
had been decreased by ≤ 50–60%. Altered
host resistance is a function of both the mag-
nitude of the decrease in NK activity and the
magnitude of the challenge to the host
(Wilson et al. 2001).
Increased levels of autoantibodies to vari-
ous organs in humans, including MBPs, have
been reported after exposure to toxic chemi-
cals (McConnachie and Zahalsky 1991, 1992;
Thrasher et al. 1987, 1990, 1993; Vojdani
et al. 1992, 1993). Thus, the increased inci-
dence of antibodies to MBP and striated and
smooth muscle (Table 3) in the GWS patients
is suggestive of autoimmunity, possibly result-
ing in tissue injury from toxic chemical expo-
sure (Cooper et al. 2002; Griem et al. 1998).
The presence of IgM antibodies to MBP
appears to indicate that an active process
involving release of these self-antigens is occur-
ring up to 8 years after injury. Central nervous
system injury has been reported in research
animals exposed to pyridostigmine bromide,
DEET (N,N-diethyl-m-toluamide), and per-
methrin (Abou-Donia et al. 2001) and in
some GWS patients, in particular, ALS (Haley
2003; Horner et al. 2003). The observations
presented here suggest that additional studies
are needed on neural damage and/or axonal
demyelinization in symptomatic Gulf War
veterans. Neural antigen and MBP antibodies
have been reported in patients with neurologic
disorders (Terryberry et al. 1998; Willison and
Yuki 2002), including ALS (Rogers et al.
1996), autism (Vojdani et al. 2002), and mul-
tiple sclerosis (Vojdani et al. 2003). Therefore,
our results are consistent with the excess of
ALS among Gulf War veterans reported by
Haley (2003). 
The GWS patients in the present study
were found to have signiﬁcantly elevated cir-
culating immune complexes (Figure 1).
Increased immune complexes have not been
previously reported to our knowledge in GWS
patients. Circulating immune complexes are
formed by excessive antigen antibody reaction.
Immune complexes have been implicated in
numerous immunopathologic conditions,
including systemic lupus erythematosus,
rheumatoid arthritis, glomerulonephritis, and
infectious induced inﬂammation (Abbas et al.
1994). Deposition of immune complexes can
occur from cell- or tissue-specific antibody–
antigen reactions, resulting in organ injury
and/or immune complex diseases (Bigazzi
et al. 1986). Thus, it would appear from these
observations on increased immune complexes
in the patient population in the present study
that inﬂammation and autoimmune reactions
may exist in a subgroup of patients with
GWS. Circulating immune complexes con-
taining IgG, IgM, and IgA antibodies can
generate a variety of substances associated with
muscle damage and the acute phase response,
activating the classic pathway of complements
(Sorensen et al. 2003).
Finally, we tested the GWS patients to
determine if an increase in antibodies to several
HSV types was present (Table 4, Figure 2). The
data clearly show that significantly increased
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Table 4. Titer levels of antibodies to viruses found in controls and patients (expressed in ELISA units).
Controls Patients Expected t-Test
Virus (mean ± SD) (mean ± SD) range range p-Value
EBV VCA IgM 197 ± 166 384 ± 400 0–300 6.627 < 0.001
CMV IgG 143 ± 121 271 ± 277 0–200 4.234 < 0.001
HSV-1 IgG 197 ± 173 491 ± 469 0–400 5.881 < 0.001
HSV-2 IgG 144 ± 162 343 ± 305 0–400 5.473 < 0.001
HHV-6 IgG 14.9 ± 8.7 42.6 ± 54.6 0–20 5.010 < 0.001
VZV IgG 15.4 ± 11.4 90.5 ± 149 0–20 4.391 < 0.001
VCA, viral capsid antigen. Controls and patients were compared using Student’s t-test. 
Figure 2. Percent elevation above the expected range of viral antibodies in controls and patients with
GWS. p < 0.01. 
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Figure 3. Hypothetical description of GWS in relation to environmental factors present in the Gulf War and
their effects on individuals with no genetic susceptibility to chemicals versus those with genetic polymor-
phism and susceptibility to chemicals resulting in immune function abnormalities and possibly immune
dysregulation. Only in the subpopulation susceptible to these environmental factors may these immune
abnormalities result in viral reactivation and symptoms similar to those of chronic fatigue and fibro-
myalgia. PAH, polycyclic aromatic hydrocarbons.
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    infectionsantibody titers occurred in the GWS patients
compared with the controls for each virus tested
(EBV, CMV, HSV-1, HSV-2, HHV-6, and
VZV; Table 4). When the observations were
limited to only affected individuals, the
increased titers to each virus was even more evi-
dent (Figure 2). Exactly when the viral infec-
tions occurred cannot be determined from
these data. However, the increased IgM anti-
bodies to EBV VCA suggest that reactivation of
EBV is probably occurring and may involve the
other viruses. To our knowledge, there has been
no other report regarding increased viral anti-
bodies in GWS patients. In addition, infections
with Mycoplasma fermentans, Mycoplasma
hominis, and Mycoplasma penetrans must also be
considered (Vojdani and Franco 1999).
Although we did not perform polymerase chain
reaction to detect DNA of these viruses, the
presence of viral antibodies and mycoplasma
DNA may be related to dysregulation of the
immune system found in this study.
Conclusion
The observations in these GWS patients sug-
gest that an alteration in the number and
function of T and B cells and NK cell activity
has occurred that may be associated with ser-
vice in the Persian Gulf. Furthermore, the
presence of antibodies to MBP and striated
and smooth muscle, increased immune com-
plexes, and increased antibody titers to several
DNA viruses indicate that viral reactivation
and/or an active inflammatory immune
process may be ongoing in some GWS
patients (Ferguson and Cassaday 2001/2001;
Patarca 2001; Rook and Zumia 1997).
Based on these observations and earlier
reports by others, we believe that GWS is a
multifactorial disease caused by exposure to a
variety of environmental conditions, for exam-
ple, xenobiotics, vaccinations, and other stres-
sor-related conditions of the Gulf War
environment as summarized in Figure 3. We
believe that the outlined multiple factors along
with genetic susceptibility due to polymor-
phism of PON1, loss of neuropathy target
esterase, glutathione S-transferase, cytochrome
P450 enzymes, or other factors may affect some
individuals, resulting in immune dysregulation
(Haley et al. 1999; Loewenstein-Lichtenstein
et al. 1995; Shields 1994; Whatt et al. 2000).
These immune functional alterations reported
herein may cause viral reactivation and induc-
tion of proinﬂammatory cytokines, resulting in
symptoms similar to those of chronic fatigue
and ﬁbromyalgia, as well as other symptoms of
GWS (Ferguson and Cassaday, 2001/2002;
Patarca 2001; Rook and Zumia 1997; Zhang
et al. 1999). The variation in individual suscep-
tibility to environmental stresses and toxicants
is a new discipline (toxicogenomics), initiated at
the National Institute of Environmental
Health Sciences, that studies the relationship
between genes and environmental stressors
(Waters et al. 2003). This new knowledge of
toxicogenomics may enable us to answer why,
upon exposure to these environmental factors,
some soldiers developed GWS and others did
not. Finally, it appears that additional studies
involving asymptomatic deployed Gulf War
veterans versus symptomatic Gulf War veter-
ans would be beneﬁcial in further understand-
ing the immunologic observations presented
herein.
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